ASH 2025
Fred Hutch Cancer Center’s latest findings in treatments for blood cancers, access to cancer therapies and biological underpinnings of disease will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH).
This year’s meeting will be held at the Orange County Convention Center in Orlando, Florida and virtually.
Visit Fred Hutch booth #1879
Featured Sessions
Scientific Program
Presenter: Marie Bleakley, MD, PhD, MMSc
Session: Novel Graft Manipulation Strategies - From Bench to Bedside
Saturday, December 6, 9:30 a.m.
Education Program
Presenter: Mary-Elizabeth Percival, MD
Session: Peri-transplant Conundrums: Optimizing Maintenance Therapy Using MRD-Directed Approaches
Saturday, December 6, 4 - 4:20 p.m.
Oral Abstract
Presenter: Andrew Jay Portuguese, MD
Session: Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium
Saturday, December 6, 10:15 a.m.
Marquee
Presenter: Rainer Storb, MD
Session: Announcement of Awards: Outstanding Service Award, ASH Mentor Awards, ASH Advancing Inclusive Excellence Award, and the Wallace H. Coulter Award for Lifetime Achievement
Sunday, December 7, 1:30 p.m.
Oral Abstract
Presenter: Jennifer Huang, MD, PhD
Session: Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia
Monday, December 8, 11:45 p.m.
Poster
Presenter: Mazyar Shadman, MD, MPH
Session: CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States
Monday, December 8, 6 - 8 p.m.
Highlights of Fred Hutch Presentations at ASH
Saturday, December 6 | Sunday, December 7 | Monday, December 8
Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium
Abstract No. 136
Presenter: Andrew Portuguese, MD
Time: 10:15 a.m.
IFNγ-driven MHC class II expression by intestinal epithelial cells dictates local cytolytic Th1 cell differentiation and intestinal stem cell loss
Abstract No. 159
Presenter: Motoko Koyama, MD, PhD
Time: 12:30 p.m.
Adverse financial events and delayed treatment initiation among patients with hematologic malignancies
Abstract No. 286
Presenter: Christopher Su, MD, MPH
Time: 2:45 p.m.
Unpredictability of caregiver gaps in multiple myeloma: Results from a survey of >1000 patients
Abstract No. 2819
Presenter: Thomas M. Kuczmarski, MD
Time: 5:30 - 7:30 p.m.
Dexamethasone dose intensity does not improve 6-month responses in newly diagnosed multiple myeloma and may contribute to hyperglycemia
Abstract No. 2207
Presenter: Gui Zhen Chen
Time: 5:30 - 7:30 p.m.
Association between extreme heat exposures and survival in patients with multiple myeloma
Abstract No. 2786
Presenter: Thomas Kuczmarski, MD
Time: 5:30 - 7:30 p.m.
Avoidance of ATG improves outcomes in double-cord blood transplantation for hematological malignancies
Abstract No. 2436
Presenter: Filippo Milano, MD, PhD
Time: 5:30 - 7:30 p.m.
Peri-transplant Conundrums: Optimizing Maintenance Therapy Using MRD-Directed Approaches
Presenter: Mary-Elizabeth Percival, MD
Time: 4 - 4:20 p.m.
Expanded Advocacy and Fight4Hematology
Presenter: Bart Scott, MD
Time: 11:15 a.m - 12:15 p.m.
Novel Graft Manipulation Strategies - From Bench to Bedside
Presenter: Marie Bleakley, MD, PhD, MMSCC
Time: 9:30 - 9:50 a.m.
CSF-1R+ macrophages orchestrate human skin chronic graft-versus-host disease
Abstract No. 588
Presenter: Julie Boiko, MD, MS
Time: 1:15 - 1:30 p.m.
DDX41-R525H mutation promotes dysplastic hematopoiesis via aberrant splicing of key regulators of HSC biology
Abstract No. 677
Presenter: Rasika Venkataraman
Time: 5:30 - 5:45 p.m.
Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)
Abstract No. 3442
Presenter: Jacob Appelbaum, MD, PhD
Time: 6 - 8 p.m.
Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)
Abstract No. 4000
Presenter: Danai Dima, MD
Time: 6 - 8 p.m.
Specific environmental factors are associated with increased rates of invasive mucormycosis infections in patients with acute leukemia and myelodysplastic syndrome
Abstract No. 3375
Presenter: Thomas Kuczmarski, MD
Time: 6 - 8 p.m.
Antibiotic risk score for acute graft-versus-host disease
Abstract No. 4253
Presenter: Armin Rashidi, MD, PhD
Time: 6 - 8 p.m.
Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia
Abstract No. 4176
Presenter: Katherine Tarlock, MD
Time: 6 - 8 p.m.
Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Advancing Inclusive Excellence Award, and the Outstanding Service Award
Presenter: Rainer Storb, MD
Time: 1:30 - 2 p.m.
Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia
Abstract No. 798
Presenter: Jennifer Huang, MD, PhD
Time: 11:45 a.m. - 12 p.m.
High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients
Abstract No. 928
Presenter: Emily Liang, MD
Time: 3:30 - 3:45 p.m.
In Vivo hematopoietic stem cell (HSC) engineering and selection with CD90-targeted multiplexed virus-like particles (MVPs) for HSC gene therapy and cancer immunotherapy
Abstract No. 1065
Presenter: Stefan Radtke, PhD
Time: 5:00 - 5:15 p.m.
CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States
Abstract No. 6272
Presenter: Mazyar Shadman, MD, MPH
Time: 6 - 8 p.m.
Next generation sequencing from dried blood spots: “Spot on CML” results from low- and middle-income countries
Abstract No. 5559
Presenter: Vivian Oehler, MD
Time: 6 - 8 p.m.
From co-occurrence to mutual exclusivity: Long read single-cell rnaseq atlas of healthy human bone marrow unveils RNA isoform landscape
Abstract No. 6133
Presenter: Elana Thieme, BS
Time: 6 - 8 p.m.
Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion
Abstract No. 6202
Presenter: Melinda Biernacki, MD
Time: 6 - 8 p.m.
Contact Our Media Relations Team
For more information or to arrange an interview, please email or call our media relations team.
